Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Equities researchers at Zacks Research boosted their Q2 2026 EPS estimates for shares of Dr. Reddy's Laboratories in a research report issued on Wednesday, October 16th. Zacks Research analyst R. Department now anticipates that the company will earn $1.00 per share for the quarter, up from their prior forecast of $0.99. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $4.11 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q3 2026 earnings at $1.01 EPS and FY2026 earnings at $4.07 EPS.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Saturday, July 27th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.10). Dr. Reddy's Laboratories had a net margin of 19.28% and a return on equity of 20.32%. The firm had revenue of $919.80 million for the quarter, compared to analysts' expectations of $861.68 million.
Separately, Barclays raised their price objective on Dr. Reddy's Laboratories from $81.00 to $87.00 and gave the company an "overweight" rating in a research report on Tuesday, July 30th.
Get Our Latest Analysis on RDY
NYSE RDY opened at $79.17 on Thursday. The stock has a 50 day simple moving average of $80.54 and a two-hundred day simple moving average of $76.29. Dr. Reddy's Laboratories has a fifty-two week low of $63.72 and a fifty-two week high of $84.46. The stock has a market cap of $13.21 billion, a P/E ratio of 19.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55.
Institutional investors have recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Dr. Reddy's Laboratories by 318.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company's stock valued at $28,411,000 after acquiring an additional 283,700 shares during the period. Millennium Management LLC increased its holdings in Dr. Reddy's Laboratories by 61.4% in the 2nd quarter. Millennium Management LLC now owns 332,502 shares of the company's stock worth $25,333,000 after buying an additional 126,472 shares during the period. Fisher Asset Management LLC grew its stake in shares of Dr. Reddy's Laboratories by 126.5% during the 4th quarter. Fisher Asset Management LLC now owns 205,280 shares of the company's stock worth $14,283,000 after purchasing an additional 114,630 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Dr. Reddy's Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after purchasing an additional 114,294 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Dr. Reddy's Laboratories by 2,197.8% during the 1st quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock valued at $8,301,000 after buying an additional 108,243 shares in the last quarter. 14.02% of the stock is owned by hedge funds and other institutional investors.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.